TD Securities raised its price target on Cannara Biotech (LOVE.TO) to C$4 from C$3.25 on Thursday.
Analysts including Derek J. Lessard maintained a Buy rating on shares of the Canadian cannabis company.
"The company continues to scale profitably, gain share with its high-velocity brands, and broaden its geographic mix; all while adding international upside without overextending," the analyst said.
(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www.mtnewswires.com/contact-us)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments